<DOC>
	<DOCNO>NCT00521404</DOCNO>
	<brief_summary>Phase 2 study determine efficacy safety CS-1008 give gemcitabine subject previously untreated unresectable ( unable surgically remove ) metastatic ( spread area beyond pancreas ) pancreatic cancer .</brief_summary>
	<brief_title>Open-label Study CS1008 Subjects With Untreated Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>Primary Objective : - To evaluate efficacy CS-1008 administer combination gemcitabine chemotherapy naive subject unresectable metastatic pancreatic cancer , base progression-free survival rate 16 week . Secondary Objectives : - To evaluate efficacy CS-1008 administer combination gemcitabine overall progression-free survival rate , objective response rate , duration response overall survival . - To determine pharmacokinetics C-1008 gemcitabine - To study potential biomarkers CS-1008 activity - To evaluate safety profile CS-1008 administer combination gemcitabine chemotherapy naive subject unresectable metastatic pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Histologically cytologically confirm resectable metastatic pancreatic cancer ; previously treat chemotherapy ; measurable disease ; 18 year age old No anticipate need major surgery radiation therapy study Heart Disease exclusion : myocardial infarction unstable angina within past 6 month ; severe unstable angina pectoris within past 6 month ; coronary peripheral artery bypass graft within past 6 mo. , etc . No clinically significant active infection history HIV No partial complete bowel obstruction Can poorly control psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>chemotherapy naive</keyword>
	<keyword>unresectable metastatic pancreatic cancer</keyword>
	<keyword>CS1008</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
</DOC>